Skip to content
Angiogenesis, the Sequel: Does Cyramza (Ramucirumab) Make a Difference for Second Line Treatment? episode artwork

Jul 17, 2014 7 min

Angiogenesis, the Sequel: Does Cyramza (Ramucirumab) Make a Difference for Second Line Treatment?

from GRACEcast Radiation Oncology Audio Hosted by cancerGRACE - H. Jack West, MD

The REVEL trial studied 1,200 non-small cell lung cancer patients to see if the drug Cyramza (ramucirumab) improved overall surival. The doctors had mixed feelings about the results.

Episode details come from the podcast's RSS feed.

Embed this episode

Ready to play

Angiogenesis, the Sequel: Does Cyramza (Ramucirumab) Make a Difference for Second Line Treatment?

0:00 7:28

No transcript yet.

Requests help us decide what to transcribe next.

Frequently asked questions

How long is this episode of GRACEcast Radiation Oncology Audio?

This episode is 7 minutes long.

When was this GRACEcast Radiation Oncology Audio episode published?

This episode was published on July 17, 2014.

Can I download this GRACEcast Radiation Oncology Audio episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.